Crucell Inks Deal with Sanofi Pasteur for Next-Generation Biologicals Against Rabies

Published on: 

Crucell N.V. (Leiden, the Netherlands) has signed an exclusive collaboration and commercialization agreement with Sanofi Pasteur (Lyon, France) for Crucell’s rabies monoclonal antibodies, the next-generation rabies biologicals to be used in association with rabies vaccine for post-exposure prophylaxis against this fatal disease.

Crucell N.V. (Leiden, the Netherlands) has signed an exclusive collaboration and commercialization agreement with Sanofi Pasteur (Lyon, France) for Crucell’s rabies monoclonal antibodies, the next-generation rabies biologicals to be used in association with rabies vaccine for post-exposure prophylaxis against this fatal disease.

Under the terms of the agreement, Crucell will continue to perform the development activities, be responsible for the manufacturing of the final product, and retain exclusive distribution rights in Europe, co-exclusive distribution rights in China, and the rights to sell to supranational organizations such as UNICEF. Crucell will receive a payment of €10 million following the execution of the agreement and will be eligible for milestone payments of up to €66.5 million.

Advertisement

Crucell releaseSanofi Pasteur release